Thus, measuring astrocytic markers, especially CSF-GFAP, would be useful for assessing astrocytopathy and clinical severity of NMO, as well as to discriminate between AQP4-antibody-positve NMOSD and MS [226,228]. The gene discussed is GFAP; the disease is myeloid sarcoma.